Joseph Haas

AbbVie gets FDA's okay for Decnupaz in a rare, aggressive type of blood cancer, giving the pharma its third approved antibody-drug conjugate and its first for hematologic malignancies.

Failure to meet a predetermined threshold for transfusion independence causes Agios to give up on its second-generation PK activator in lower-risk myelodysplastic syndrome.

As part of a recent emphasis on building a neurology portfolio, Servier is paying up to $2.65bn for assets led by Edgewise's Phase III Becker muscular dystrophy candidate.

With vormatrigine missing the primary endpoint in a Phase II/III study, Praxis halts enrollment in a follow-on study, but it has two other seizure drugs under FDA review.

Plus deals involving Sanofi/Owkin, Everest/Mabworks, Avenzo/Rallybio, T-CURX/Pantherna, Gilead/Kaken, SK Bioscience/VECOL and more.

Roche and Nurix entered into a global alliance for BTK degrader bexobrutideg in hematologic cancers and possible immunology indications, where the big pharma has had a mixed experience in MS.

Venture capital funding is readily available to biotechs with later-stage programs, but for earlier-stage firms, a financing squeeze is on and narrowing focus is a possible solution, EY report authors said.

UBS analyst Michael Yee says Lilly's Zepbound, Foundayo and retatrutide are well positioned to stay on top in the obesity market despite Novo Nordisk's early Wegovy pill momentum.

In its latest Biotech Beyond Borders report, EY analysts argue that the US biotech sector should focus on competing better with China, rather than attempting to constrain it.

With two proprietary platforms for ultrasound-driven delivery and targeting as well as novel therapeutic payloads, the biotech believes it can improve upon viral vector gene therapies.